Akebia Therapeutics
AKBA · Nasdaq · United States
Share price · AKBA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AKBA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+32.8%
Nothing announced by AKBA that day or the session before.
- 5 Nov 2026-38.8%
- 28 Oct 2026+15.8%
Nothing announced by AKBA that day or the session before.
- 26 Oct 2026+13.6%
- 20 Oct 2026-9.1%
Nothing announced by AKBA that day or the session before.
- 6 Aug 2026-26.0%
- 20 May 2026+12.8%
Nothing announced by AKBA that day or the session before.
- 19 May 2026-11.4%
Nothing announced by AKBA that day or the session before.
- 7 May 2026-20.3%
- 16 Apr 2026-12.9%
Nothing announced by AKBA that day or the session before.
Share of unusual movement by asset
For each asset, the share of AKBA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Vadadustat(Vafseo) | Approved | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
| Phase 2 | C3d / Factor HProtein / enzyme therapeutic | IgA NephropathyLupus Nephritis | |
| Phase 2 | Soluble guanylate cyclaseSmall molecule | Chronic Kidney DiseaseFocal Segmental Glomerulosclerosis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
2028 (1)
February 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $37M | $16M | $160M | $14M$2.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $49M | $14M | $157M | $8.9M$3.5M operating cash flow | report ↗ |
| 2026-Q1 | $54M | $15M | $164M | $9.1M-$21M operating cash flow | report ↗ |
| 2025-Q3 | $59M | $15M | $168M | —$28M operating cash flow | report ↗ |
| 2025-Q2 | $62M | $11M | $139M | —$22M operating cash flow | report ↗ |
| 2025-Q1 | $57M | $9.8M | $115M | —-$14M operating cash flow | report ↗ |
| 2024-Q3 | $37M | $8.5M | $36M | $20M-$6.7M operating cash flow | report ↗ |
| 2024-Q2 | $44M | $7.7M | $41M | $8.6M-$10M operating cash flow | report ↗ |
| 2024-Q1 | $33M | $9.7M | $44M | $18M-$19M operating cash flow | report ↗ |
| 2023-Q3 | $42M | $13M | $48M | $14M-$7.2M operating cash flow | report ↗ |
| 2023-Q2 | $56M | $20M | $55M | $11M$3.6M operating cash flow | report ↗ |
| 2023-Q1 | $40M | $20M | $60M | $26M-$18M operating cash flow | report ↗ |
| 2022-Q3 | $49M | $27M | $148M | $52M$34M operating cash flow | report ↗ |
| 2022-Q2 | $127M | $26M | $147M | —-$31M operating cash flow | report ↗ |
| 2022-Q1 | $62M | $44M | $178M | $62M-$22M operating cash flow | report ↗ |
| 2021-Q3 | $49M | $40M | $209M+ $0 short-term inv. | $60M-$56M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $236M | $62M | $187M | $1.3M$68M operating cash flow | report ↗ |
Akebia Therapeutics reported FY2025 revenue of $236.2M, up 47.5% YoY, and R&D spend of $62.36M, up 65.6% YoY. Cash and equivalents stood at $186.54M, with a net loss of $5.34M and quarterly net burn of $5.35M.
The company continued to commercialize Auryxia and Vafseo and advance pipeline candidates AKB-097 and praliciguat. During the year, Akebia entered into an asset purchase agreement with Q32, amended its Cyclerion license arrangement, completed a public stock offering, and added Tranche C under its term loan facility.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $160M | $38M | $54M | $17M-$41M operating cash flow | report ↗ |
| 2023-FY | $195M | $63M | $45M | $13M-$23M operating cash flow | report ↗ |
| 2022-FY | $293M | $129M | $93M | $23M-$73M operating cash flow | report ↗ |
| 2021-FY | $214M | $148M | $152M+ $0 short-term inv. | $71M-$253M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($87K), 16 sales ($963K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. · director, CEO and President | Option exercise | 350,000 | $0.63 | $221K | Form 4 |
| 2026-08-06 | Butler John P. · director, CEO and President | Option exercise (derivative) | 350,000 | — | — | Form 4 |
| 2026-06-29 | Ostrowski Erik · SVP, CFO, CBO & Treasurer | Open-market sale | 56,019 | $1.11 | $62K | Form 4 |
| 2026-06-17 | ADAMS ADRIAN · director | Award / grant | 35,700 | — | — | Form 4 |
| 2026-06-17 | ZUMWALT LEANNE M · director | Award / grant | 35,700 | — | — | Form 4 |
| 2026-06-17 | FRIESON RON · director | Award / grant | 35,700 | — | — | Form 4 |
| 2026-06-17 | ROGERS MICHAEL W · director | Award / grant | 35,700 | — | — | Form 4 |
| 2026-06-17 | Smith Cynthia · director | Award / grant | 35,700 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 170 reporting institutions held 101.7M shares ($137.4M, 36.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 18,693,296 | $26.0M |
| 2 | STATE STREET CORP | 11,614,006 | $16.1M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 11,166,710 | $15.5M |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 6,452,252 | $9.0M |
| 5 | GOLDMAN SACHS GROUP INC | 3,602,827 | $5.0M |
| 6 | CITIGROUP INC | 2,854,586 | $4.0M |
| 7 | BANK OF AMERICA CORP /DE/ | 2,763,362 | $3.8M |
| 8 | Qube Research & Technologies Ltd | 2,395,215 | $3.3M |
| 9 | MILLENNIUM MANAGEMENT LLC | 2,384,713 | $3.3M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,215,441 | $3.1M |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,015,577 | $2.8M |
| 12 | Nantahala Capital Management, LLC | 2,000,000 | $2.8M |
| 13 | NORTHERN TRUST CORP | 1,945,586 | $2.7M |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 1,833,128 | $2.5M |
| 15 | AQR CAPITAL MANAGEMENT LLC | 1,792,620 | $2.5M |